摘要
目的 :评价CYPRA2 1- 1、NSE对肺癌诊断和预后的价值。方法 :将肺癌患者分为NSCLC组和SCLC组 ,良性疾病为对照组。所有患者均收集患、健侧BALF、静脉血 ,测CYFRA2 1- 1、NSE。结果 :NSCLC中CYFRA2 1- 1明显高于SCLC和对照组。SCLC中NSE则显著高于NSCLC和对照组。二项指标均以患侧BALF增高明显 ,而且NSE是提示SCLC预后、CYFR2 1- 1则是提示NSCLC预后的有价值的指标 ;联合检测正确率增高 ,以患侧最优。结论 :联合检测患侧BALF中CYFRA2 1- 1、NSE诊断肺癌阳性率最高 ,对预后判断有重要价值。
Objective: To evaluate the diagnostic performance and prognostic role of the cancer marker CYFRA21-1 and NSE in the lung cancer.Methods: This study includes three groups: one group with non-small cell lung cancer, one group with small cell lung cancer and a control group with benign lung disease. BALF were collected from the both sides of lung in all subjects and venous sample were collected at the same time. The concentration of CYFRA21-1 and NSE were determined.Results: The CYFRA21-1 levels in BALF and venous in the group with NSCLS was significantly higher than the groups with SCLS and benign lung disease.The NSE levels in BALF and venous in the group with SCLC was significantly higher than in the groups with NSCLS and benign lung disease. The CYFRA21-1 and NSE concentration from the unhealthy lung side increased more significantly than from healthy side,and NSE have prognostic singnificance in SCLC, CYFRA21-1 have prognostic singnificance in NSCLS. The way of combining CYFRA21-1 and NSE from the unhealthy lung side is best.Conclusions: The sensitivity is highest to the diagnosis of lung cancer when combining CYFRA21-1 and NSE in BALF from the unhealthy lung side,may be proposed for use in the prognosis.
出处
《中国内镜杂志》
CSCD
2003年第4期9-12,共4页
China Journal of Endoscopy
基金
武汉市科委 (wk) 2 0 0 2 10 0 1